Hikma Pharmaceuticals Plc (LON:HIK) insider Said Darwazah acquired 50,000 shares of Hikma Pharmaceuticals Plc stock in a transaction that occurred on Monday, September 26th. The stock was acquired at an average cost of GBX 2,078 ($27.12) per share, with a total value of £1,039,000 ($1,356,219.81).
Said Darwazah also recently made the following trade(s):
- On Wednesday, September 28th, Said Darwazah bought 10,000 shares of Hikma Pharmaceuticals Plc stock. The shares were purchased at an average cost of GBX 2,085 ($27.22) per share, with a total value of £208,500 ($272,157.68).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 2049.00 on Friday. The company has a 50-day moving average of GBX 2,176.69 and a 200-day moving average of GBX 2,245.79. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,575.00 and a 1-year high of GBX 2,703.00. The company’s market cap is GBX 4.63 billion.
A number of research analysts have weighed in on HIK shares. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, September 23rd. Barclays PLC reissued an “overweight” rating and set a GBX 2,900 ($37.85) target price on shares of Hikma Pharmaceuticals Plc in a research report on Friday, September 9th. Numis Securities Ltd reissued a “hold” rating and set a GBX 2,660 ($34.72) target price on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, August 24th. Jefferies Group cut their target price on shares of Hikma Pharmaceuticals Plc from GBX 2,990 ($39.03) to GBX 2,500 ($32.63) and set a “buy” rating for the company in a research report on Monday, September 12th. Finally, Citigroup Inc. lowered shares of Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($33.94) target price for the company. in a research report on Thursday, August 4th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of GBX 2,520.90 ($32.91).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.